LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 58,700 shares, an increase of 178.2% from the November 30th total of 21,100 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 89,100 shares, the short-interest ratio is currently 0.7 days.

LAVA Therapeutics Stock Up 0.1 %

LVTX traded up $0.00 during trading on Friday, hitting $0.99. The company’s stock had a trading volume of 253,037 shares, compared to its average volume of 515,669. LAVA Therapeutics has a one year low of $0.88 and a one year high of $6.47. The business’s 50 day simple moving average is $1.56 and its 200-day simple moving average is $1.73. The firm has a market cap of $25.18 million, a PE ratio of -0.96 and a beta of 0.43.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LVTX. HC Wainwright dropped their price target on LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, December 20th. Citizens Jmp cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, JMP Securities reiterated a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.33.

Institutional Trading of LAVA Therapeutics

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in LAVA Therapeutics during the third quarter valued at about $32,000. XTX Topco Ltd purchased a new stake in shares of LAVA Therapeutics during the 2nd quarter worth approximately $55,000. Finally, Pathway Financial Advisors LLC lifted its position in LAVA Therapeutics by 70.8% during the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after purchasing an additional 42,500 shares during the last quarter.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.